ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
oleh: Naveen Kumar
| Format: | Article |
|---|---|
| Diterbitkan: | Wolters Kluwer Medknow Publications 2022-01-01 |
Deskripsi
No description available for this item.